clinical trial · NCT03289962
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.·phase1·completed·n = 272
MelanomaNon-Small Cell Lung CancerBladder CancerColorectal CancerTriple Negative Breast CancerRenal CancerHead and Neck CancerOther Solid CancersAutogene cevumeranAtezolizumab
brief summary
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 \[anti-PD-L1\] antibody).
started
Dec 21, 2017
primary completion
Jul 1, 2025
completion
Jul 1, 2025
last updated
Jul 4, 2025
official title
A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol